Abbott Diagnostics restructuring
This article was originally published in The Gray Sheet
Business unit will lay off about 1,100 employees worldwide and reorganize into four operations focusing on immunochemistry, hematology, molecular and blood glucose monitoring. Worldwide diagnostics sales of $733 mil. in the third quarter were basically flat (up 0.8%), including a 9% decline in U.S. diagnostics revenues to $288 mil. Abbott notes it has hired Bio-Reg and AccuReg as new third-party consultants to assist in resolving its 1999 FDA consent decree. The diagnostics restructuring is part of a larger plan to increase bottom-line accountability and save $80-100 mil. annually by 2005, Abbott notes. Company-wide, 2,000 positions will be cut, or 3% of Abbott's workforce, and ten facilities shuttered. A fourth-quarter charge of $100-125 mil. will be recorded...
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.